Midas Biotek Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
as on 23-12-2024
- Paid Up Capital ₹ 3.00 M
as on 23-12-2024
- Company Age 23 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.01 Cr
as on 23-12-2024
- Revenue -5.72%
(FY 2020)
- Profit -31.13%
(FY 2020)
- Ebitda 506.44%
(FY 2020)
- Net Worth 2.67%
(FY 2020)
- Total Assets 5.79%
(FY 2020)
About Midas Biotek
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 3.00 M.
The company currently has active open charges totaling ₹1.01 Cr.
Krishna Pulluri, Giri Areti, Hari Chikoti, and One other member serve as directors at the Company.
- CIN/LLPIN
U01119TG2001PTC038042
- Company No.
038042
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Nov 2001
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Midas Biotek?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Krishna Pulluri  | Director | 09-Nov-2001 | Current |
| Giri Areti | Director | 08-Mar-2004 | Current |
| Hari Chikoti | Director | 09-Nov-2001 | Current |
| Srinivas Mukka | Director | 09-Nov-2001 | Current |
Financial Performance of Midas Biotek.
Midas Biotek Private Limited, for the financial year ended 2020, experienced Minor drop in revenue, with a 5.72% decrease. The company also saw a substantial fall in profitability, with a 31.13% decrease in profit. The company's net worth moved up by a moderate rise of 2.67%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Midas Biotek?
In 2019, Midas Biotek had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Gladcare Formulations Private LimitedActive 18 years 6 monthsKrishna Pulluri and Srinivas Mukka are mutual person
Charges (Loans)
₹10.10 M
₹0
Charges Breakdown by Lending Institutions
- Small Industries Development Bank Of India : 0.80 Cr
- Oriental Bank Of Commerce : 0.21 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 07 Mar 2014 | Oriental Bank Of Commerce | ₹2.10 M | Open |
| 25 Mar 2009 | Small Industries Development Bank Of India | ₹8.00 M | Open |
How Many Employees Work at Midas Biotek?
Unlock and access historical data on people associated with Midas Biotek, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Midas Biotek, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Midas Biotek's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.